GRN-1201 + sargramostim

GRN-1201 + sargramostim is a combination immunotherapeutic regimen under investigation for cancer treatment, specifically as a cancer peptide vaccine plus an immunostimulatory cytokine. - **GRN-1201** is a synthetic cancer vaccine comprising four HLA-A2-restricted peptides derived from tumor-associated antigens (TAAs), designed to elicit a cytotoxic T lymphocyte-mediated response against cancer cells expressing those antigens[3][4]. - **Sargramostim (brand name: Leukine)** is a recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF), administered with the vaccine to boost the immune system and enhance antigen presentation and effector T cell expansion[3][4][7]. - The combination is developed to augment immune response against tumor cells by promoting both innate and adaptive immunity, with GRN-1201 driving tumor-specific T cell responses and sargramostim improving dendritic cell function and antigen presentation[4][7]. - Initial clinical studies combined GRN-1201 and sargramostim as immunotherapy for melanoma and are ongoing for non-small cell lung cancer (NSCLC) in combination with checkpoint inhibitors[1][3][4][5]. - GRN-1201 developer: BrightPath Biotherapeutics (formerly GreenPeptide).

Other names

GM-CSF